Lab M Gains ISO 17025 Accreditation from UKAS
News Nov 13, 2015
The quality control laboratory of Lab M’s facilities in Heywood, UK, has been granted ISO 17025:2005 accreditation by the United Kingdom Accreditation Service (UKAS).
Lab M’s schedule of accreditation covers both the physical and microbiological performance testing of the company’s ready-to-use Pinnacle™ media range. The five methods that were accredited include pH, sterility, fill volume, qualitative performance testing and quantitative performance testing. All methods are based on the new requirements of BS EN ISO 11133:14.
“The requirements of BS EN ISO 11133:14 have been considered throughout the expansion of our Pinnacle range. This newly published standard has been a major focus of all manufacturers and users of culture media,” said Lyn Richards, quality assurance and regulatory affairs manager at Lab M. “The implementation of the new requirements of the standard to all of our QC testing has been a major focus for Lab M over the last 12 months, and to have the methods accredited to ISO 17025 is the next step to demonstrate the quality of the testing of our products. This accreditation will also support the production quality of our ready-to-use media range.”
Lab M’s QC laboratory is a purpose-built facility that is staffed by an experienced team of microbiologists, some of whom have worked with Lab M for more than 20 years. The QC laboratory also has an ongoing investment programme with regards to equipment.
UKAS is the national accreditation body for the United Kingdom, appointed by government, to assess organizations that provide certification, testing, inspection and calibration services.
Accreditation determines the technical competence and integrity of organizations offering testing, inspection, calibration, verification and certification services.
In August, Lab M was acquired by Neogen Corporation, a world-wide leader in the development of food and animal safety products and services.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
3rd Annual DIGI-TECH PHARMA 2019 Conference & Expo
May 21 - May 22, 2019